Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Palatucci, Polo Universitario Annunziata, 98168 Messina, Italy.
Department of Scienze Biomediche Sperimentali e Cliniche, Sezione di Scienze Biochimiche, University of Firenze, Viale Morgagni 50, 50134 Firenze, Italy.
Molecules. 2021 Jan 10;26(2):330. doi: 10.3390/molecules26020330.
Diabetes mellitus (DM) is a complex disease which currently affects more than 460 million people and is one of the leading cause of death worldwide. Its development implies numerous metabolic dysfunctions and the onset of hyperglycaemia-induced chronic complications. Multiple ligands can be rationally designed for the treatment of multifactorial diseases, such as DM, with the precise aim of simultaneously controlling multiple pathogenic mechanisms related to the disease and providing a more effective and safer therapeutic treatment compared to combinations of selective drugs. Starting from our previous findings that highlighted the possibility to target both aldose reductase (AR) and protein tyrosine phosphatase 1B (PTP1B), two enzymes strictly implicated in the development of DM and its complications, we synthesised 3-(5-arylidene-4-oxothiazolidin-3-yl)propanoic acids and analogous 2-butenoic acid derivatives, with the aim of balancing the effectiveness of dual AR/PTP1B inhibitors which we had identified as designed multiple ligands (DMLs). Out of the tested compounds, exhibited well-balanced AR/PTP1B inhibitory effects at low micromolar concentrations, along with interesting insulin-sensitizing activity in murine C2C12 cell cultures. The SARs here highlighted along with their rationalization by in silico docking experiments into both target enzymes provide further insights into this class of inhibitors for their development as potential DML antidiabetic candidates.
糖尿病(DM)是一种复杂的疾病,目前影响着超过 4.6 亿人,是全球主要死亡原因之一。它的发展涉及到许多代谢功能障碍和高血糖引起的慢性并发症。可以合理设计多种配体来治疗多因素疾病,如糖尿病,其精确目的是同时控制与疾病相关的多种致病机制,并提供比选择性药物组合更有效和更安全的治疗方法。从我们之前的研究结果出发,我们强调了同时针对醛糖还原酶(AR)和蛋白酪氨酸磷酸酶 1B(PTP1B)的可能性,这两种酶严格参与糖尿病及其并发症的发展,我们合成了 3-(5-芳基亚甲基-4-氧代噻唑烷-3-基)丙酸和类似的 2-丁烯酸衍生物,旨在平衡我们确定为设计多重配体(DML)的双重 AR/PTP1B 抑制剂的有效性。在所测试的化合物中,化合物 表现出在低微摩尔浓度下对 AR/PTP1B 的良好抑制作用,并且在小鼠 C2C12 细胞培养物中具有有趣的胰岛素增敏活性。这里突出的 SAR 及其通过计算机对接实验对两种靶酶的合理化提供了进一步的见解,为将这些抑制剂开发为有潜力的 DML 抗糖尿病候选药物提供了依据。